Weight Gain After Smoking Cessation and Atherosclerotic Low-Density Lipoprotein Marker

Mami Iida

Department of Internal Medicine and Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan

See article vol. 23: 1270-1275

Smoking is one of the major risk factors for atherosclerosis and develops coronary artery disease, cerebrovascular disease, and peripheral artery disease¹. It adversely affects the platelet and vascular endothelial function, inflammation, and oxidative stress². Moreover, it increases the incidence of atherogenic lipid profile (higher levels of triglycerides and low-density lipoprotein cholesterol (LDL-C); and lowers the levels of high-density lipoprotein cholesterol (HDL-C))³; insulin resistance, including type 2 diabetes⁴; and metabolic syndrome⁵. Therefore, smoking cessation (SC) is the most important matter for the prevention and treatment of atherosclerotic cardiovascular diseases (CVD). On the other hand, SC is often accompanied by weight gain. Recent meta-analysis reported that SC is associated with a mean increase of 4–5 kg in body weight after 12 months of abstinence, and most weight gain occurs within 3 months of quitting⁶. Weight gain itself is also a risk factor for CVD. SC causes an improvement in insulin sensitivity and an increase in HDL-C, whereas obesity after SC might paradoxically contribute to insulin resistance and atherogenic lipid profile^{2, 7}. Therefore, the relationship between SC and weight gain could remain to be a highly relevant subject for further research for preventing and treating CVD.

The α 1-antitrypsin–low-density lipoprotein complex (AT-LDL) and serum amyloid A-LDL complex (SAA-LDL) are oxidatively modified LDL complexes and are closely associated with both smoking and obesity, which induce oxidative stress and inflammation^{8, 9}. One-year time course changes of these two

markers and other serum metabolic and inflammatory parameters, as well as body mass index (BMI) and waist circumference, after SC are evaluated in the present study¹⁰. The authors show that the serum levels of AT-LDL and SAA-LDL were unchanged from baseline to 3 months after SC but these levels significantly decreased from 3 months to 1 year after SC. Although abdominal obesity progressively worsened after SC, the beneficial effect of non-smoking clearly overcomes potential vascular risks by cessation-associated obesity at 1 year after SC. The authors previously reported a significant decrease in serum AT-LDL values among patients with a BMI increase smaller than the median at 3 months after SC¹¹. However, large weight gain after SC perturbs the decrease in AT-LDL at 3 months after SC.

We consider that the reduced post-cessation weight gain can bring in earlier beneficial effects of SC for oxidatively modified LDL complexes. Furthermore, post-cessation weight gain is indicated to be an essential reason why smokers, especially women, fail to initiate SC or relapse after initiating SC. It is hereafter worth considering for SC programs and therapies, including pharmacological treatment, designed for reducing post-cessation weight gain.

Conflicts of Interest

None.

References

- 1) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb, 2013; 20: 733-742
- 2) Messner B, Bernhard D. Smoking and cardiovascular dis-

Address for correspondence: Mami Iida, Department of Internal Medicine and Cardiology, Gifu Prefectural General Medical Center, 4-6-1, Noishiki, Gifu-City, Gifu 500-8717, Japan
E-mail: iida-mami@gifu-hp.jp

Received: August 22, 2016

Accepted for publication: August 22, 2016

- ease: Mechanisms of endothelial dysfunction and early atherogenesis. *Arterioscler Thromb Vasc Biol*, 2014; 34: 509-515
- 3) Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ*, 1989; 298: 784-788
 - 4) Tonstad S. Cigarette smoking, smoking cessation, and diabetes. *Diabetes Research and Clinical Practice*, 2009; 85: 4-13
 - 5) Nakanishi N, Takatorige T, Suzuki K. Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. *Ind Health*, 2005; 43: 295-301
 - 6) Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. *BMJ*, 2012; 345: e4439
 - 7) Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH. Effects of smoking and smoking cessation on lipids and lipoproteins: Outcomes from a randomized clinical trial. *Am Heart J*, 2011; 161: 145-151
 - 8) Kotani K, Satoh N, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Oishi M, Yamakage H, Yamada K, Hattori M, Shimatsu A: The Japan Obesity and Metabolic Syndrome Study Group. A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome. *Atherosclerosis*, 2009; 204: 526-531
 - 9) Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, Abe M, Ono K, Morimoto T, Fujita M, Shimatsu A, Takahashi Y, Hasegawa K. α 1-Antitrypsin low-density-lipoprotein serves as a marker of smoking-specific oxidative stress. *J Atheroscler Thromb*, 2012; 19: 47-58
 - 10) Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, Akao M, Morimoto T, Takahashi Y, Hasegawa K. Time-dependent changes of atherosclerotic LDL complexes after smoking cessation. *J Atheroscler Thromb*, 2016; 23: 1270-1275
 - 11) Komiyama M, Wada H, Ura S, Yamakage H, Satoh-Asahara N, Shimada S, Akao M, Koyama H, Kono K, Shimatsu A, Takahashi Y, Hasegawa K. The effects of weight gain after smoking cessation on atherogenic α 1-antitrypsin-low-density lipoprotein. *Heart Vessels*, 2015; 30: 734-739